Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Lower House Clears Immunization Act Revision
Japan’s Lower House on June 30 passed a bill to revise the Immunization Act, which would pave the way for drugs shown to be as effective as vaccines in preventing infectious diseases to be used for immunization under the law.…
To read the full story
Related Article
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
June 10, 2026
- LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
- MHLW Moves Toward Immunization Act Revision for RSV Antibody Drugs
May 21, 2026
- Japan Eyes June Submission of Immunization Act Bill to Cover Antibody Drugs
May 18, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- Japan Starts Review on Scope of Drugs Eligible for Immunization Use, with Beyfortus in Focus
January 23, 2026
- Japan Panel OKs NIP Use of Maternal RSV Vaccine from FY2026
November 21, 2025
- Japan Panel Backs NIP Use of High-Dose Flu Shot; Talks Continue on RSV Prevention
October 27, 2025
- Sanofi Sets Sights on 2026 NIP Inclusion of RSV Drug Beyfortus in Japan
October 2, 2025
- Japan to Prepare Fact Sheets on RSV Vaccine, Antibody
September 5, 2024
REGULATORY
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
- Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
- LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026
- Lower House Clears Immunization Act Revision
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…